Argentina
· Delayed Price · Currency is ARS Bioceres Crop Solutions Statistics
Total Valuation
BCBA:BIOX has a market cap or net worth of ARS 331.54 billion. The enterprise value is 670.68 billion.
| Market Cap | 331.54B |
| Enterprise Value | 670.68B |
Important Dates
The next estimated earnings date is Monday, September 8, 2025.
| Earnings Date | Sep 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -4.74% |
| Shares Change (QoQ) | -0.59% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 35.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 37.16 |
| PS Ratio | 0.81 |
| PB Ratio | 0.89 |
| P/TBV Ratio | 14.64 |
| P/FCF Ratio | 7.90 |
| P/OCF Ratio | 6.66 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.99, with an EV/FCF ratio of 15.98.
| EV / Earnings | -69.01 |
| EV / Sales | 1.50 |
| EV / EBITDA | 12.99 |
| EV / EBIT | 27.60 |
| EV / FCF | 15.98 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.82 |
| Debt / EBITDA | 6.23 |
| Debt / FCF | 7.30 |
| Interest Coverage | 0.88 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 2.27% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -10.19B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.87% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -58.87% |
| 50-Day Moving Average | 5,415.40 |
| 200-Day Moving Average | 7,426.78 |
| Relative Strength Index (RSI) | 48.36 |
| Average Volume (20 Days) | 42,898 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.29 |
Income Statement
In the last 12 months, BCBA:BIOX had revenue of ARS 411.31 billion and -9.72 billion in losses. Loss per share was -154.77.
| Revenue | 411.31B |
| Gross Profit | 161.29B |
| Operating Income | 24.05B |
| Pretax Income | -20.14B |
| Net Income | -9.72B |
| EBITDA | 44.08B |
| EBIT | 24.05B |
| Loss Per Share | -154.77 |
Balance Sheet
The company has 33.48 billion in cash and 306.52 billion in debt, giving a net cash position of -273.05 billion.
| Cash & Cash Equivalents | 33.48B |
| Total Debt | 306.52B |
| Net Cash | -273.05B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 371.65B |
| Book Value Per Share | 5,297.02 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 49.75 billion and capital expenditures -7.78 billion, giving a free cash flow of 41.96 billion.
| Operating Cash Flow | 49.75B |
| Capital Expenditures | -7.78B |
| Free Cash Flow | 41.96B |
| FCF Per Share | n/a |
Margins
Gross margin is 39.21%, with operating and profit margins of 5.85% and -2.36%.
| Gross Margin | 39.21% |
| Operating Margin | 5.85% |
| Pretax Margin | -4.90% |
| Profit Margin | -2.36% |
| EBITDA Margin | 10.72% |
| EBIT Margin | 5.85% |
| FCF Margin | 10.20% |
Dividends & Yields
BCBA:BIOX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.74% |
| Shareholder Yield | n/a |
| Earnings Yield | -2.93% |
| FCF Yield | 12.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 24, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Jan 24, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |